CCM
CDLX icon

Check Capital Management’s Cardlytics CDLX Stock Holding History

Check Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,450
Closed -$123K – 51
2025
Q2 		$123K Buy
7,450
+1,280
+21% +$22.1K ﹤0.01% 49
2025
Q1 		$112K Buy
6,170
+550
+10% +$15.7K ﹤0.01% 50
2024
Q4 		$209K Buy
5,620
+555
+11% +$21.2K 0.01% 48
2024
Q3 		$162K Buy
5,065
+477
+10% +$26.5K 0.01% 49
2024
Q2 		$377K Buy
4,588
+340
+8% +$36.8K 0.01% 33
2024
Q1 		$615K Buy
4,248
+1,928
+83% +$163K 0.02% 26
2023
Q4 		$214K Buy
2,320
+285
+14% +$29K 0.01% 43
2023
Q3 		$336K Buy
2,035
+845
+71% +$110K 0.01% 33
2023
Q2 		$75.2K Buy
1,190
+110
+10% +$6.66K ﹤0.01% 39
2023
Q1 		$36.7K Buy
1,080
+20
+2% +$1.04K ﹤0.01% 39
2022
Q4 		$61.3K Buy
1,060
+12
+1% +$741 ﹤0.01% 38
2022
Q3 		$99K Buy
+1,048
New +$149K 0.01% 37
2022
Q2 		– Sell
-656
Closed -$360K – 43
2022
Q1 		$360K Buy
+656
New +$396K 0.01% 35

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Check Capital Management's CDLX Position: Q3 2025 in Review

Check Capital Management sold out of Cardlytics (CDLX) in Q3 2025, closing a stake of 7,450 shares — an estimated $123K sold.

Check Capital Management first reported a position in CDLX in Q1 2022 and held it in 13 quarters. The position peaked at $615K in Q1 2024. 81 funds tracked by Wall St. Rank hold CDLX as of Q3 2025.

  • Check Capital Management reported no remaining Cardlytics position as of Q3 2025 after selling out during the quarter.
  • Check Capital Management sold 7,450 Cardlytics shares in Q3 2025, an estimated $123K.
  • Check Capital Management first reported a position in Cardlytics in Q1 2022 and held it in 13 quarters.
  • Check Capital Management's Cardlytics position peaked at $615K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Cardlytics as of Q3 2025.

Based on Check Capital Management's 13F filing for Q3 2025, filed 6 Nov 2025.